Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis
暂无分享,去创建一个
Hui Ling | Armin Gerger | Marek Svoboda | Cristina Ivan | Johannes Haybaeck | Gerald Hoefler | Xinna Zhang | Ajay Goel | G. Calin | H. Ling | C. Ivan | A. Gerger | Xinna Zhang | O. Slabý | M. Svoboda | M. Pichler | J. Haybaeck | A. Goel | Y. Okugawa | George Adrian Calin | Martin Pichler | V. Stiegelbauer | P. Vychytilová-Faltejsková | E. Winter | Matthew Goblirsch | A. Wulf‐Goldenberg | Masahisa Ohtsuka | G. Hoefler | Petra Vychytilova-Faltejskova | Ondrej Slaby | Yoshinaga Okugawa | Verena Stiegelbauer | Elke Winter | Matthew Goblirsch | Annika Wulf-Goldenberg | Masahisa Ohtsuka | M. Goblirsch | A. Goel
[1] D G Altman,et al. What do we mean by validating a prognostic model? , 2000, Statistics in medicine.
[2] D. Birnbaum,et al. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth , 2011, Oncogene.
[3] R. Spizzo,et al. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. , 2012, Gastroenterology.
[4] Huawei Zeng,et al. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. , 2013, Gastroenterology.
[5] Rebecca L. Siegel Mph,et al. Colorectal cancer statistics, 2014 , 2014 .
[6] R. Spizzo,et al. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis , 2015, Gut.
[7] Yanlei Ma,et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer , 2011, Gut.
[8] Y. Toiyama,et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis , 2012, Gut.
[9] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[10] Yuzhuo Wang,et al. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression , 2015, Oncotarget.
[11] G. Calin,et al. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients , 2015, British Journal of Cancer.
[12] G. Calin,et al. MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.
[13] H. Brenner,et al. MicroRNA Signatures: Novel Biomarker for Colorectal Cancer? , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[14] J. Goeman,et al. MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[15] A. Krasinskas,et al. Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. , 2011, Seminars in oncology.
[16] H. Lenz,et al. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. , 2015, Hematology/oncology clinics of North America.
[17] Kieran Sheahan,et al. Controversies in the pathological assessment of colorectal cancer. , 2014, World journal of gastroenterology.
[18] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[19] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[20] E. Van Cutsem,et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Stefano Volinia,et al. MicroRNA Profiles Discriminate among Colon Cancer Metastasis , 2014, PloS one.
[22] Wei Wei,et al. Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression , 2015, Nature Communications.
[23] Jian Lu,et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. , 2013, The Lancet. Oncology.
[24] S. Gill,et al. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes. , 2014, Cancer treatment reviews.
[25] W. Xie,et al. MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes , 2014, Cell Communication and Signaling.
[26] U. Capitanio,et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.
[27] A. Jemal,et al. Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[28] Philip Quirke,et al. The future of the TNM staging system in colorectal cancer: time for a debate? , 2007, The Lancet. Oncology.
[29] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] Sabine Tejpar,et al. Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.
[31] P. Ubezio,et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Tseng,et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer , 2012, Oncogene.
[33] M. Asslaber,et al. A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients , 2014, Clinical Cancer Research.
[34] J. Foekens,et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer , 2013, Genome research.
[35] M. Ferracin,et al. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab , 2015, Oncotarget.